Evaluating The Clinical Efficacy Of Recombinant Human Interleukin-11 For Treatment Of Thrombocytopenia

Objective To study the relatoionship between thrombelatography variables in patients with thrombocytopenia after using recombinant human IL-11.Methods According to clinical diagnosis,60 patients whose thrombocyte were less than 70x109/L were randomly divided into the rhIL-11 group and control group.All the patients received active antibiotics and other comprehensive treatment.The rhIL-11 group was given rhIL-11 1.5mg/d,then compared with the results of platelet count ,coagulation fuction and thrombelastography.Results ①30 cases of RhIL-11 patients, including 19 cases of male, 11 cases of female, mean age is 55.33 + 5.57,mean APACHEII score is 20.8 + 7.8. The control group of 30 cases,including20 males and 10 females, mean age is 56.33 + 4.78, mean APACHEII score is22.3 + 6.5. The two groups had no statistically significant difference in gender and age of patients,APACHEII score. (P > 0.05). ②rhIL-11 group and control group, the platelet count before treatment had no significant difference (P > 0.05). Before and after treatment in two groups of coagulation four (prothrombin time,activated part prothrombin time,plasma thrombin time, fibrinogen r differences had no statistical significance difference. (P > 0.05) 7 days after treatment, platelet count of patients in the IL-11 group was higher than the control group at fifth day, there was significant difference between two groups (P < 0.05). Two groups of patients with thrombosis of thromboelastography related indexes in the treatment of no statistical significance (P > 0.05), rhIL-11 group before and after treatment, R, K, angle without obvious difference, the difference was not statistically significant (P > 0.05), increased after administration of Ma compared with that before treatment, the difference is statistically significant (P< 0.05).③ In rhIL-11 group the total effective rate was 96.7%, control group total effective rate was 60%. The rhIL-11 group was significantly higher than the control group. ④The patients in the rhIL-11 group the average ICU stay time was 12 + 3.22 days, patients in the control group the average ICU stay time was 11.34 + 4.47 days. Two days in the ICU group was no statistically significant difference (P > 0.05). After 28 days, rhIL-11 group 10 cases died, the mortality rate was 33.3%. The control group 12 cases died, the mortality rate was 40%.The mortality rate between the two groups was not statistically significant. ⑤The ROC curve by ROC curve analysis, the MA value of the sensitivity and specificity were respectively 0.650, 0.733. ⑥The rhIL-11 group had no obvious adverse reactions.Conclusion The rhIL-11 can promote the recovery of the platelet count and fuction in the ICU thrombocytopenia patients,with its clinical efficacy safe and reliable.